<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03832608</url>
  </required_header>
  <id_info>
    <org_study_id>H1542733812827</org_study_id>
    <secondary_id>H1542733812827</secondary_id>
    <nct_id>NCT03832608</nct_id>
  </id_info>
  <brief_title>Sarcopenia Cut-points and Functionality in Older Adults</brief_title>
  <acronym>SARCOFUNC</acronym>
  <official_title>Relationship Between the Sarcopenia Diagnostic Cut-points and Functionality in Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a cross-sectional study conducted in older adults living in Valencia Province in&#xD;
      order to establish the cut-off points of the multicriteria diagnostic of sarcopenia through&#xD;
      functionality and frailty variables.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcopenia is a geriatric syndrome that involves a gradual and generalized loss of the mass&#xD;
      and strength of the skeletal muscles. Currently, there is an international debate about the&#xD;
      criteria and reference values for the sarcopenia diagnosis, and the main scientific societies&#xD;
      encourage improving research on this. The biggest problem lies in the assessment of the&#xD;
      diagnostic criterion of muscle mass while the criterion of muscular strength seems safer and&#xD;
      more robust. Experts point out the need to adjust the muscle mass indexes to the&#xD;
      characteristics of the population studied, and the convenience of relating the three&#xD;
      diagnostic criteria of sarcopenia (muscle mass and strength, and walking speed) with other&#xD;
      variables that report about functionality and frailty in older adults.&#xD;
&#xD;
      The main objective is to establish different cut-off points for the diagnostic criteria of&#xD;
      sarcopenia and relate them with other instruments for assessing functionality in older&#xD;
      population of Valencia Province.&#xD;
&#xD;
      To this purpose, data will be collected through various tests and questionnaires about:&#xD;
      clinical, demographic and anthropometric characteristics; muscle mass; muscle strength; walk&#xD;
      speed; physical and cognitive function; nutritional status; self-perception of health;&#xD;
      comorbidity and frailty. With this information it will be possible, as primary outcome, to&#xD;
      determine a more sensitive, reliable and valid muscle mass index to predict sarcopenia, and,&#xD;
      as a secondary outcome, to establish the relationship between the multicriteria diagnostic of&#xD;
      sarcopenia with the functional and frailty variables.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 8, 2019</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>First criteria of sarcopenia diagnostic: hand grip strength</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Muscle strength measured by the isometric hand grip strength (reference: Age and Aging. 2010;39:412-23).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First criteria of sarcopenia diagnostic: knew extension strength</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Muscle strength measured by the isometric knew extension (reference: Phys Ther. 1996;76(3):248-59).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>First criteria of sarcopenia diagnostic: elbow flexion strength</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Muscle strength measured by the isometric elbow flexion (reference: Phys Ther. 1996;76(3):248-59).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Second criteria of sarcopenia diagnostic: muscle mass</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Muscle mass estimated by Bioimpedance analysis (BIA) (reference: J Aging Phys Act. 2015;23(4):597-606).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Third criteria of sarcopenia diagnostic: walk speed</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Walk speed measured by the Short Physical Performance Balance test (SPPB) (reference: J Gerontol A Biol Sci Med Sc 2000; 55(4):M221-31.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functionality: Modified Baecke Questionnaire</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Functionality measured by the Modified Baecke Questionnaire (reference: Med Clin.2007;129:326-32). The Modified Baecke Questionnaire results in a score to classify people as high, moderate, or low in daily physical activity, based on tertiles.&#xD;
Work Index = 0 1 +12 + 13 + 14 + 15 + 16 + 17 + I8)/8 Sport Index = 0 9 + 110 + II1 + I12)/4 Leisure Time Index = 0 ' 3 + 114 + 115 + 116 + 117 + 118 + I19V7 Total Index = work index + sports index + leisure time index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality: Barthel Index</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Functionality measured by the Barthel Index (reference: Rev Esp Geriatr Gerontol.1993;28:32-40). Range from 0 to 100 score. High score of 100 means total independent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality: Lawton and Brody Questionnaire</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Functionality measured by the Lawton and Brody Questionnaire (reference: Gerontologist.1969;9:179-86).Range from 0 to 8 score. High score of 8 means total independent to perform daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frailty: Fried Scale</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Frailty measured by the Fried Scale (reference: J Gerontol A Biol Sci Med Sc. 2001;56(3):M146-56). It is a scale with 5 domains: weight loss, self-reported exhaustion, physical activity, walking speed, and weakness. It has a total score ≥ 5 points. A frail person is who scores 3 to 5; is prefrail when scores is 1 to 2, and robust if scores is 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frailty:Frail Scale</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Frailty measured by the Frail Scale (reference: J Nutr Health Aging. 2012;16(7):601-8). It has a total score of 5 points. The more score the more frailty. As in Fried scale, participants with scores 3 to 5 is frail person; with scores 1 to 2 is prefrail, and robust if scores is 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frailty: Kihon Check List (KCL)</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Frailty measured by the Kihon Check List (reference: Geriatr Gerontol Int. 2016;16(6):709-15). The KCL is a simple self-reporting yes/no survey consisting of 25 questions structured into seven domains /dimensions. A total score ≥ 10 points allow to identify a frail person and each domain can identify the specific need.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidity</measure>
    <time_frame>The cohort group will be assessed in one day visit.</time_frame>
    <description>Comorbidity measured by Abbreviated Charslon Index (reference: J Chron Dis.1987;40:373-83). Range from 0 to 10 score. High score of 10 means high comorbidity; 0 means absence of comorbidity.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Diagnostic</condition>
  <arm_group>
    <arm_group_label>Older adults and Sarcopenia</arm_group_label>
    <description>Older adults with and without Sarcopenia living in Valencia Province.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>There is not intervention to be administered, only collection of data through various tests and questionnaires.</description>
    <arm_group_label>Older adults and Sarcopenia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Older adults (+65 years) living in Valence Province.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  People aged &gt; 65 years&#xD;
&#xD;
          -  Residents in Valencia Province (Living-Community, Day-Centers and institutionalized)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lobo Mini-exam cognoscitive &lt; 18 score&#xD;
&#xD;
          -  Any disorder that prevents from performing the assessment tests.&#xD;
&#xD;
          -  Recent hospitalization or who are in a acute process of any illness (less one month).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria A Cebrià i Iranzo, PT, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mercè Balasch i Bernat, PT, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Arnal Gómez, PT, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trinidad Sentandreu Mañó, PT, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria A Tortosa Chuliá, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalia Cezón Serrano, PT</last_name>
    <role>Study Chair</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose M Tomás, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Forcano Sanjuán, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitari i Politècnic La Fe (Valencia)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Armonea Group</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.</citation>
    <PMID>20392703</PMID>
  </reference>
  <reference>
    <citation>Masanes F, Culla A, Navarro-Gonzalez M, Navarro-Lopez M, Sacanella E, Torres B, Lopez-Soto A. Prevalence of sarcopenia in healthy community-dwelling elderly in an urban area of Barcelona (Spain). J Nutr Health Aging. 2012 Feb;16(2):184-7. doi: 10.1007/s12603-011-0108-3.</citation>
    <PMID>22323356</PMID>
  </reference>
  <reference>
    <citation>Salva A, Serra-Rexach JA, Artaza I, Formiga F, Rojano I Luque X, Cuesta F, Lopez-Soto A, Masanes F, Ruiz D, Cruz-Jentoft AJ. [Prevalence of sarcopenia in Spanish nursing homes: Comparison of the results of the ELLI study with other populations]. Rev Esp Geriatr Gerontol. 2016 Sep-Oct;51(5):260-4. doi: 10.1016/j.regg.2016.02.004. Epub 2016 Apr 9. Spanish.</citation>
    <PMID>27068239</PMID>
  </reference>
  <reference>
    <citation>Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, Lee JS, Lee WJ, Lee Y, Liang CK, Limpawattana P, Lin CS, Peng LN, Satake S, Suzuki T, Won CW, Wu CH, Wu SN, Zhang T, Zeng P, Akishita M, Arai H. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014 Feb;15(2):95-101. doi: 10.1016/j.jamda.2013.11.025.</citation>
    <PMID>24461239</PMID>
  </reference>
  <reference>
    <citation>Lee WJ, Liu LK, Peng LN, Lin MH, Chen LK; ILAS Research Group. Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan longitudinal aging study. J Am Med Dir Assoc. 2013 Jul;14(7):528.e1-7. doi: 10.1016/j.jamda.2013.03.019. Epub 2013 May 10.</citation>
    <PMID>23664768</PMID>
  </reference>
  <reference>
    <citation>Ethgen O, Beaudart C, Buckinx F, Bruyere O, Reginster JY. The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action. Calcif Tissue Int. 2017 Mar;100(3):229-234. doi: 10.1007/s00223-016-0220-9. Epub 2016 Dec 24.</citation>
    <PMID>28012107</PMID>
  </reference>
  <results_reference>
    <citation>Cebria I Iranzo MA, Arnal-Gomez A, Tortosa-Chulia MA, Balasch-Bernat M, Forcano S, Sentandreu-Mano T, Tomas JM, Cezon-Serrano N. Functional and Clinical Characteristics for Predicting Sarcopenia in Institutionalised Older Adults: Identifying Tools for Clinical Screening. Int J Environ Res Public Health. 2020 Jun 22;17(12):4483. doi: 10.3390/ijerph17124483.</citation>
    <PMID>32580427</PMID>
  </results_reference>
  <results_reference>
    <citation>Arnal-Gomez A, Cebria I Iranzo MA, Tomas JM, Tortosa-Chulia MA, Balasch-Bernat M, Sentandreu-Mano T, Forcano S, Cezon-Serrano N. Using the Updated EWGSOP2 Definition in Diagnosing Sarcopenia in Spanish Older Adults: Clinical Approach. J Clin Med. 2021 Mar 2;10(5):1018. doi: 10.3390/jcm10051018.</citation>
    <PMID>33801427</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 31, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Valencia</investigator_affiliation>
    <investigator_full_name>Maria dels Angels Cebria i Iranzo, PT, PhD</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Older adult</keyword>
  <keyword>Sarcopenia</keyword>
  <keyword>Frailty</keyword>
  <keyword>Functionality</keyword>
  <keyword>Muscle strength</keyword>
  <keyword>Muscle mass</keyword>
  <keyword>Walk speed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03832608
org study id: H1542733812827
secondary id: H1542733812827
nct id: NCT03832608
lead sponsor: 
has dmc: No
This is a cross-sectional study conducted in older adults living in Valencia Province in
      order to establish the cut-off points of the multicriteria diagnostic of sarcopenia through
      functionality and frailty variables.
Sarcopenia is a geriatric syndrome that involves a gradual and generalized loss of the mass
      and strength of the skeletal muscles. Currently, there is an international debate about the
      criteria and reference values for the sarcopenia diagnosis, and the main scientific societies
      encourage improving research on this. The biggest problem lies in the assessment of the
      diagnostic criterion of muscle mass while the criterion of muscular strength seems safer and
      more robust. Experts point out the need to adjust the muscle mass indexes to the
      characteristics of the population studied, and the convenience of relating the three
      diagnostic criteria of sarcopenia (muscle mass and strength, and walking speed) with other
      variables that report about functionality and frailty in older adults.

      The main objective is to establish different cut-off points for the diagnostic criteria of
      sarcopenia and relate them with other instruments for assessing functionality in older
      population of Valencia Province.

      To this purpose, data will be collected through various tests and questionnaires about:
      clinical, demographic and anthropometric characteristics; muscle mass; muscle strength; walk
      speed; physical and cognitive function; nutritional status; self-perception of health;
      comorbidity and frailty. With this information it will be possible, as primary outcome, to
      determine a more sensitive, reliable and valid muscle mass index to predict sarcopenia, and,
      as a secondary outcome, to establish the relationship between the multicriteria diagnostic of
      sarcopenia with the functional and frailty variables.
observational model: Cohort
time perspective: Cross-Sectional
measure: First criteria of sarcopenia diagnostic: hand grip strength
time frame: The cohort group will be assessed in one day visit.
description: Muscle strength measured by the isometric hand grip strength (reference: Age and Aging. 2010;39:412-23).
measure: First criteria of sarcopenia diagnostic: knew extension strength
time frame: The cohort group will be assessed in one day visit.
description: Muscle strength measured by the isometric knew extension (reference: Phys Ther. 1996;76(3):248-59).
measure: First criteria of sarcopenia diagnostic: elbow flexion strength
time frame: The cohort group will be assessed in one day visit.
description: Muscle strength measured by the isometric elbow flexion (reference: Phys Ther. 1996;76(3):248-59).
measure: Second criteria of sarcopenia diagnostic: muscle mass
time frame: The cohort group will be assessed in one day visit.
description: Muscle mass estimated by Bioimpedance analysis (BIA) (reference: J Aging Phys Act. 2015;23(4):597-606).
measure: Third criteria of sarcopenia diagnostic: walk speed
time frame: The cohort group will be assessed in one day visit.
description: Walk speed measured by the Short Physical Performance Balance test (SPPB) (reference: J Gerontol A Biol Sci Med Sc 2000; 55(4):M221-31.
measure: Functionality: Modified Baecke Questionnaire
time frame: The cohort group will be assessed in one day visit.
description: Functionality measured by the Modified Baecke Questionnaire (reference: Med Clin.2007;129:326-32). The Modified Baecke Questionnaire results in a score to classify people as high, moderate, or low in daily physical activity, based on tertiles.
Work Index = 0 1 +12 + 13 + 14 + 15 + 16 + 17 + I8)/8 Sport Index = 0 9 + 110 + II1 + I12)/4 Leisure Time Index = 0 ' 3 + 114 + 115 + 116 + 117 + 118 + I19V7 Total Index = work index + sports index + leisure time index.
measure: Functionality: Barthel Index
time frame: The cohort group will be assessed in one day visit.
description: Functionality measured by the Barthel Index (reference: Rev Esp Geriatr Gerontol.1993;28:32-40). Range from 0 to 100 score. High score of 100 means total independent.
measure: Functionality: Lawton and Brody Questionnaire
time frame: The cohort group will be assessed in one day visit.
description: Functionality measured by the Lawton and Brody Questionnaire (reference: Gerontologist.1969;9:179-86).Range from 0 to 8 score. High score of 8 means total independent to perform daily activities.
measure: Frailty: Fried Scale
time frame: The cohort group will be assessed in one day visit.
description: Frailty measured by the Fried Scale (reference: J Gerontol A Biol Sci Med Sc. 2001;56(3):M146-56). It is a scale with 5 domains: weight loss, self-reported exhaustion, physical activity, walking speed, and weakness. It has a total score ≥ 5 points. A frail person is who scores 3 to 5; is prefrail when scores is 1 to 2, and robust if scores is 0.
measure: Frailty:Frail Scale
time frame: The cohort group will be assessed in one day visit.
description: Frailty measured by the Frail Scale (reference: J Nutr Health Aging. 2012;16(7):601-8). It has a total score of 5 points. The more score the more frailty. As in Fried scale, participants with scores 3 to 5 is frail person; with scores 1 to 2 is prefrail, and robust if scores is 0.
measure: Frailty: Kihon Check List (KCL)
time frame: The cohort group will be assessed in one day visit.
description: Frailty measured by the Kihon Check List (reference: Geriatr Gerontol Int. 2016;16(6):709-15). The KCL is a simple self-reporting yes/no survey consisting of 25 questions structured into seven domains /dimensions. A total score ≥ 10 points allow to identify a frail person and each domain can identify the specific need.
measure: Comorbidity
time frame: The cohort group will be assessed in one day visit.
description: Comorbidity measured by Abbreviated Charslon Index (reference: J Chron Dis.1987;40:373-83). Range from 0 to 10 score. High score of 10 means high comorbidity; 0 means absence of comorbidity.
arm group label: Older adults and Sarcopenia
description: Older adults with and without Sarcopenia living in Valencia Province.
intervention type: Other
intervention name: No intervention
description: There is not intervention to be administered, only collection of data through various tests and questionnaires.
arm group label: Older adults and Sarcopenia
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 65 Years
maximum age: N/A
healthy volunteers: No
last name: Maria A Cebrià i Iranzo, PT, PhD
role: Principal Investigator
affiliation: University of Valencia
last name: Mercè Balasch i Bernat, PT, PhD
role: Study Chair
affiliation: University of Valencia
last name: Anna Arnal Gómez, PT, PhD
role: Study Chair
affiliation: University of Valencia
last name: Trinidad Sentandreu Mañó, PT, PhD
role: Study Chair
affiliation: University of Valencia
last name: Maria A Tortosa Chuliá, PhD
role: Study Chair
affiliation: University of Valencia
last name: Natalia Cezón Serrano, PT
role: Study Chair
affiliation: University of Valencia
last name: Jose M Tomás, PhD
role: Study Chair
affiliation: University of Valencia
last name: Silvia Forcano Sanjuán, MD
role: Study Chair
affiliation: Hospital Universitari i Politècnic La Fe (Valencia)
facility: 
country: Spain
citation: Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M; European Working Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034. Epub 2010 Apr 13.
PMID: 20392703
citation: Masanes F, Culla A, Navarro-Gonzalez M, Navarro-Lopez M, Sacanella E, Torres B, Lopez-Soto A. Prevalence of sarcopenia in healthy community-dwelling elderly in an urban area of Barcelona (Spain). J Nutr Health Aging. 2012 Feb;16(2):184-7. doi: 10.1007/s12603-011-0108-3.
PMID: 22323356
citation: Salva A, Serra-Rexach JA, Artaza I, Formiga F, Rojano I Luque X, Cuesta F, Lopez-Soto A, Masanes F, Ruiz D, Cruz-Jentoft AJ. [Prevalence of sarcopenia in Spanish nursing homes: Comparison of the results of the ELLI study with other populations]. Rev Esp Geriatr Gerontol. 2016 Sep-Oct;51(5):260-4. doi: 10.1016/j.regg.2016.02.004. Epub 2016 Apr 9. Spanish.
PMID: 27068239
citation: Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, Chou MY, Chen LY, Hsu PS, Krairit O, Lee JS, Lee WJ, Lee Y, Liang CK, Limpawattana P, Lin CS, Peng LN, Satake S, Suzuki T, Won CW, Wu CH, Wu SN, Zhang T, Zeng P, Akishita M, Arai H. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014 Feb;15(2):95-101. doi: 10.1016/j.jamda.2013.11.025.
PMID: 24461239
citation: Lee WJ, Liu LK, Peng LN, Lin MH, Chen LK; ILAS Research Group. Comparisons of sarcopenia defined by IWGS and EWGSOP criteria among older people: results from the I-Lan longitudinal aging study. J Am Med Dir Assoc. 2013 Jul;14(7):528.e1-7. doi: 10.1016/j.jamda.2013.03.019. Epub 2013 May 10.
PMID: 23664768
citation: Ethgen O, Beaudart C, Buckinx F, Bruyere O, Reginster JY. The Future Prevalence of Sarcopenia in Europe: A Claim for Public Health Action. Calcif Tissue Int. 2017 Mar;100(3):229-234. doi: 10.1007/s00223-016-0220-9. Epub 2016 Dec 24.
PMID: 28012107
citation: Cebria I Iranzo MA, Arnal-Gomez A, Tortosa-Chulia MA, Balasch-Bernat M, Forcano S, Sentandreu-Mano T, Tomas JM, Cezon-Serrano N. Functional and Clinical Characteristics for Predicting Sarcopenia in Institutionalised Older Adults: Identifying Tools for Clinical Screening. Int J Environ Res Public Health. 2020 Jun 22;17(12):4483. doi: 10.3390/ijerph17124483.
PMID: 32580427
citation: Arnal-Gomez A, Cebria I Iranzo MA, Tomas JM, Tortosa-Chulia MA, Balasch-Bernat M, Sentandreu-Mano T, Forcano S, Cezon-Serrano N. Using the Updated EWGSOP2 Definition in Diagnosing Sarcopenia in Spanish Older Adults: Clinical Approach. J Clin Med. 2021 Mar 2;10(5):1018. doi: 10.3390/jcm10051018.
PMID: 33801427
responsible party type: Principal Investigator
investigator affiliation: University of Valencia
investigator full name: Maria dels Angels Cebria i Iranzo, PT, PhD
investigator title: Assistant professor
mesh term: Sarcopenia
sharing ipd: Undecided